This firm currently holds 623.62
M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating Clovis Oncology may have difficulties to generate enough cash to satisfy its financial obligations.
We provide trade advice to complement the prevailing
expert consensus on Clovis Oncology. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Clovis Oncology Investment Alerts
Clovis investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Clovis Oncology performance across your portfolios.Please check all
investment alerts for Clovis
Clovis Oncology Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Clovis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clovis Oncology competition to find
correlations between indicators driving the intrinsic value of Clovis.
Another angle On Clovis Oncology
The company reported the previous year's revenue of 156.09
M. Net Loss for the year was (299.09
M) with profit before overhead, payroll, taxes, and interest of 128.39
M.
| 2019 | 2020 | 2021 | 2022 (projected) |
Receivables | 22.74 M | 28.39 M | 25.56 M | 27.57 M | Inventories | 26.52 M | 30.71 M | 27.64 M | 26.32 M |
Margins Breakdown
Clovis profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Clovis Oncology itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Clovis Oncology profit margins.
| EBITDA Margin | (1.61) |
| Gross Margin | 0.79 |
| Profit Margin | (1.92) |
Clovis Oncology Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. Clovis Oncology Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. Furthermore, Clovis Oncology Revenue Per Employee is relatively stable at the moment. Clovis Oncology Earnings Before Interest Taxes and Depreciation Amortization USD is relatively stable at the moment. Clovis Oncology Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The latest value of Clovis Oncology Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -239,881,289. Furthermore, Clovis Oncology Revenue Per Employee is relatively stable at the moment.
Another 3 percent spike for Clovis Oncology
Latest mean deviation is at 5.51.
As of the 2nd of April, Clovis Oncology shows the
risk adjusted performance of
(0.027136), and Mean Deviation of 5.51. Clovis Oncology
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Clovis Oncology, which can be compared to its rivals. Please confirm
Clovis Oncology coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to decide if Clovis Oncology is priced correctly, providing market reflects its regular price of 2.5 per share. Please also double-check Clovis Oncology
total risk alpha, which is currently at 0.2767 to validate the company can sustain itself at a future point.
While some other firms in the biotechnology industry are either recovering or due for a correction, Clovis Oncology may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 2nd of April 2022, we see that Clovis Oncology hyperactively responds to market trends. The enterprise is
undervalued with
high odds of financial turmoil within the next 24 months. Our actual 90 days buy-or-sell advice on the enterprise is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Clovis Oncology. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
